2,3-DihydroheveaflavoneCAS# 110382-42-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 110382-42-8 | SDF | Download SDF |
PubChem ID | 91884905 | Appearance | Yellow powder |
Formula | C33H26O10 | M.Wt | 582.6 |
Type of Compound | Flavonoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 5-hydroxy-8-[2-hydroxy-5-[(2S)-5-hydroxy-7-methoxy-4-oxo-2,3-dihydrochromen-2-yl]phenyl]-7-methoxy-2-(4-methoxyphenyl)chromen-4-one | ||
SMILES | COC1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C=C3O)OC)C4=C(C=CC(=C4)C5CC(=O)C6=C(C=C(C=C6O5)OC)O)O | ||
Standard InChIKey | BZHLYSWNQTVRDR-MHZLTWQESA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
2,3-Dihydroheveaflavone Dilution Calculator
2,3-Dihydroheveaflavone Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.7164 mL | 8.5822 mL | 17.1644 mL | 34.3289 mL | 42.9111 mL |
5 mM | 0.3433 mL | 1.7164 mL | 3.4329 mL | 6.8658 mL | 8.5822 mL |
10 mM | 0.1716 mL | 0.8582 mL | 1.7164 mL | 3.4329 mL | 4.2911 mL |
50 mM | 0.0343 mL | 0.1716 mL | 0.3433 mL | 0.6866 mL | 0.8582 mL |
100 mM | 0.0172 mL | 0.0858 mL | 0.1716 mL | 0.3433 mL | 0.4291 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 3-O-Methyltagitinin F
Catalog No.:BCN5991
CAS No.:110382-37-1
- Ch 55
Catalog No.:BCC7241
CAS No.:110368-33-7
- S 32826
Catalog No.:BCC7678
CAS No.:1103672-43-0
- Bavisant dihydrochloride hydrate
Catalog No.:BCC1404
CAS No.:1103522-80-0
- CGS 19755
Catalog No.:BCC6986
CAS No.:110347-85-8
- FD-838
Catalog No.:BCN6396
CAS No.:110341-78-1
- α-Bungarotoxin
Catalog No.:BCC7264
CAS No.:11032-79-4
- Santalol
Catalog No.:BCN8352
CAS No.:11031-45-1
- CI 966 hydrochloride
Catalog No.:BCC7010
CAS No.:110283-66-4
- Bacoside A
Catalog No.:BCC8127
CAS No.:11028-00-5
- Agnuside
Catalog No.:BCN5990
CAS No.:11027-63-7
- Amrubicin
Catalog No.:BCC3640
CAS No.:110267-81-7
- Meclizine hydrochloride
Catalog No.:BCC9017
CAS No.:1104-22-9
- Higenamine HCl
Catalog No.:BCN2831
CAS No.:11041-94-4
- Gelsemiol
Catalog No.:BCN5992
CAS No.:110414-77-2
- Dolastatin 10
Catalog No.:BCC4056
CAS No.:110417-88-4
- ML-7 hydrochloride
Catalog No.:BCC1770
CAS No.:110448-33-4
- BYK 204165
Catalog No.:BCC2449
CAS No.:1104546-89-5
- Crotastriatine
Catalog No.:BCN2101
CAS No.:11051-94-8
- 6,11-Di-O-acetylalbrassitriol
Catalog No.:BCN7273
CAS No.:110538-20-0
- Scutebarbatine F
Catalog No.:BCN5377
CAS No.:910099-78-4
- Albrassitriol
Catalog No.:BCN7274
CAS No.:110557-39-6
- Salermide
Catalog No.:BCC7867
CAS No.:1105698-15-4
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
The representativeness of eligible patients in type 2 diabetes trials: a case study using GIST 2.0.[Pubmed:29025047]
J Am Med Inform Assoc. 2017 Sep 13. pii: 4157244.
Objective: The population representativeness of a clinical study is influenced by how real-world patients qualify for the study. We analyze the representativeness of eligible patients for multiple type 2 diabetes trials and the relationship between representativeness and other trial characteristics. Methods: Sixty-nine study traits available in the electronic health record data for 2034 patients with type 2 diabetes were used to profile the target patients for type 2 diabetes trials. A set of 1691 type 2 diabetes trials was identified from ClinicalTrials.gov, and their population representativeness was calculated using the published Generalizability Index of Study Traits 2.0 metric. The relationships between population representativeness and number of traits and between trial duration and trial metadata were statistically analyzed. A focused analysis with only phase 2 and 3 interventional trials was also conducted. Results: A total of 869 of 1691 trials (51.4%) and 412 of 776 phase 2 and 3 interventional trials (53.1%) had a population representativeness of <5%. The overall representativeness was significantly correlated with the representativeness of the Hba1c criterion. The greater the number of criteria or the shorter the trial, the less the representativeness. Among the trial metadata, phase, recruitment status, and start year were found to have a statistically significant effect on population representativeness. For phase 2 and 3 interventional trials, only start year was significantly associated with representativeness. Conclusions: Our study quantified the representativeness of multiple type 2 diabetes trials. The common low representativeness of type 2 diabetes trials could be attributed to specific study design requirements of trials or safety concerns. Rather than criticizing the low representativeness, we contribute a method for increasing the transparency of the representativeness of clinical trials.
Clinical manifestations of Rathke's cleft cysts and their natural progression during 2 years in children and adolescents.[Pubmed:29025202]
Ann Pediatr Endocrinol Metab. 2017 Sep;22(3):164-169.
PURPOSE: Rathke's cleft cyst (RCC) is an asymptomatic benign lesion. With increased interest in pediatric endocrinology, the prevalence of RCCs in children is also increasing. However, the clinical relevance and proper management of RCC is not well defined in children. Therefore, we investigated the clinical manifestations and radiologic features of RCC in children and adolescents, as well as the natural progression of RCC. METHODS: We retrospectively reviewed the medical records of 91 children and adolescents with RCC diagnosed with magnetic resonance imaging (MRI) in Severance Children's Hospital from January 2006 to December 2015. The clinical, hormonal, and imaging findings were analyzed in patient groups classified according to age. The size of each cyst was assessed in sixty patients who underwent follow-up MRI during the 2 years. RESULTS: Female patients were predominant (64 vs. 27). The common clinical features at presentation were endocrine dysfunction (59.3%), headache (23.0%), and dizziness (4.4%). Symptoms related to endocrine disorders were more frequent in younger patients. In 7 patients managed surgically, the cysts were significantly larger and more frequently located in the suprasellar region. Of 60 nonsurgical patients with a follow-up MRI performed within 2 years after the diagnosis, the RCC size increased in about 26.7% (n=16). CONCLUSIONS: Although 94.4% of the patients with RCC had clinical symptoms, surgery was performed in only about 7.5% of patients. RCC is associated with pituitary insufficiency, thus, baseline and follow-up endocrine function tests are required. Additionally, regular MRI follow-up is required in long-term period to monitor change in size.
The Relationship between Vitamin D and Type 2 Diabetes Is Intriguing: Glimpses from the Spect-China Study.[Pubmed:29024934]
Ann Nutr Metab. 2017;71(3-4):195-202.
OBJECTIVE: Vitamin D is a multifunctional vitamin for our body. Type 2 diabetes mellitus (T2DM) is a common metabolic disease. Whether T2DM affects the serum 25(OH)D level has not been reported. The objective of this study was to reveal the extent to which vitamin D is present in the population in East China and to explore the relationship between serum 25(OH)D and T2DM. METHODS: The cohort was selected based on a large investigation named Survey on Prevalence in East China including 12,702 participants aged 21-92 years old. All the participants completed the questionnaire and went through a physical examination. Fasting blood samples were collected to test serum 25(OH)D and other metabolism-related indicators. AVONA was used to test the significance of differences among groups. Multinomial logistic regression was used to assess the association of T2DM with serum 25(OH)D level. RESULTS: The overall percentage of vitamin D deficiency was 80.55% (male 74.1%, female 85.0%). Men with lower serum 25(OH)D level had high value in homeostasis model assessment of insulin resistance and HbA1c. The serum 25(OH)D level of those who were diagnosed with T2DM was higher than that in non-diabetics. The serum 25(OH)D level of pre-diabetes was the highest. T2DM patients trended to have higher serum 25(OH)D levels. CONCLUSION: Vitamin D deficiency is common among the people in East-China. T2DM patients had higher levels of serum 25(OH)D. The relationship between vitamin D and T2DM is intriguing. It seemed that vitamin D was either irrelevant directly to T2DM or resisted in T2DM patients.